Skip to main content
MS Research, Treatment and Education and The MS Trust have merged. Read our merger announcement here

new drugs for Relapsing Remitting MS - A comment on benefits and risks

In an article on Multiple Sclerosis News Today Ed Tobias, who has MS, discusses news items on the increasing awareness of possible risks associated with some of the new MS Disease Modifying Drugs (DMDs).

He writes: “…all disease-modifying treatments have the possibility of side effects, and some are more serious than others. We who use the treatments should always be doing so with our eyes wide open and fully informed of the risks.

Continue reading

The two Bobs take to the Devon coast once more for MS Research

When most of us are taking it easy Exmouth resident Bob Baker and his friend Bob Richards will be dusting off their hiking boots once again and taking on their annual 14-mile New Year’s Day charity trek from Sidmouth to Exmouth to raise funds for MS Research on the 1st January 2019.

Continue reading

MS Research - funding education

Earlier this year Sona Mistry, a final year medical student at the University of Sheffield, presented her research on Autologous hematopoietic stem cell transplant (AHSCT) for people with relapse-remitting MS at the American Academy of Neurology 70th Annual Meeting, the world’s largest gathering of neurologists. The trip was funded by MS Research as we strongly believe that educational development and information sharing is vital to further our understanding of MS.

Continue reading

Inspirational Stories

In recognition of MS Awareness week we would like to share two stories written by inspirational people living with MS.

Viv’s Story

Viv was diagnosed with MS in 2011, this is the story of Viv’s experiences in her own words.

Continue reading

Cookie Policy

This website uses cookies that are necessary to its functioning and required to achieve the purposes illustrated in the privacy policy. By accepting this OR scrolling this page OR continuing to browse, you agree to our privacy policy.